NCT00652379

Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients: Impact on Insulin Sensitivity, Glucose Tolerance, and Pharmacoeconomics

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: University of Aarhus · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy. Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.

Conditions

• Acromegaly
• Insulin Resistance
• Impaired Glucose Tolerance

Interventions

Type	Name	Description
DRUG	Pegvisomant	Pegvisomant s.c 15-30 mg 2 times a week
DRUG	Somatostatin analog (lanreotide or octreotide)	Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog

Timeline

• Start date: 2008-06-01
• Primary completion: 2009-11-01
• Completion: 2011-05-01
• First posted: 2008-04-03
• Last updated: 2012-01-26

Locations

1 site across 1 country: Denmark